SGMO Sangamo Therapeutics, Inc.

4.75
+0  (10%)
Previous Close 4.30
Open 4.40
Price To book 2.24
Market Cap 336.66M
Shares 70,875,000
Volume 1,185,039
Short Ratio 10.12
Av. Daily Volume 579,697

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated early 2017 with data due late 2017 or early 2018.
SB-318
MPS Type 1
Phase 1/2 data due late 2017 or early 2018.
SB-FIX
Hemophilia B
Phase 1/2 trial to be initiated early 2017 with data due late 2017 or early 2018.
SB-913
MPS Type 2
Data presented Dec 2015
SB-728-1401
HIV/AIDS
Data presented Dec 2015
SB-728-1101
HIV/AIDS

Latest News

  1. Sangamo Announces The Retirement Of Its Founder And Genome Editing Pioneer Edward Lanphier From The Board Of Directors
  2. Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy
  3. Sangamo Therapeutics Announces Participation In The ARM 5th Annual Cell & Gene Therapy Investor Day
  4. Sangamo Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SGMO-US : April 18, 2017
  5. ETFs with exposure to Sangamo Therapeutics, Inc. : April 7, 2017
  6. Sangamo Therapeutics Announces Presentation of New Data Demonstrating Significant Reduction of Tau Expression Using Proprietary ZFP Gene Regulation Technology
  7. ETFs with exposure to Sangamo Therapeutics, Inc. : March 27, 2017
  8. Sangamo Therapeutics, Inc. :SGMO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  9. Sangamo Therapeutics, Inc. :SGMO-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  10. Sangamo Therapeutics Announces Presentation At The Cowen And Company 37th Annual Health Care Conference
  11. Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 Genome Editing Treatment for MPS II
  12. Sangamo reports 4Q loss
  13. Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results
  14. Sangamo Therapeutics Announces Chief Financial Officer Succession
  15. Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome Editing Therapeutic For MPS I
  16. Sangamo Therapeutics Announces Fourth Quarter And Full Year 2016 Conference Call And Webcast
  17. Sangamo Therapeutics Announces Upcoming Presentations At The 13th Annual WORLDSymposium™ Meeting
  18. ETFs with exposure to Sangamo Therapeutics, Inc. : January 20, 2017
  19. Biotech Premarket Movers: SGMO, IPXL, PTLA
  20. Biotech Premarket Movers: IPXL, SGMO, ARLZ